Literature DB >> 33177929

Formulation and In Vitro Evaluation of Telmisartan Nanoparticles Prepared by Emulsion-Solvent Evaporation Technique.

Naile ÖztÜrk1, Aslı Kara2, İmran Vural3.   

Abstract

OBJECTIVES: Telmisartan (TLM) is an antihypertensive drug that has been shown to have antiproliferative effects on cancer cells. It has low solubility and suboptimal oral bioavailability. To investigate the potential anticancer effect of TLM on breast cancer cells, poly (D, L-lactide) (PLA) nanoparticles were formulated with the benefit of improving its solubility.
MATERIALS AND METHODS: TLM-loaded PLA nanoparticles were prepared by emulsion solvent evaporation. The effects of sonication time and polymer:drug ratio on nanoparticle size and drug encapsulation were investigated. TLM-loaded nanoparticles were tested against MCF-7 and MD-AMB-231 breast cancer cell lines for antiproliferative effects.
RESULTS: Nanoparticles with mean particle size 272 nm and 79% encapsulation efficiency were obtained. Sustained release TLM nanoparticles (40% in 24 h) decreased cell viability to 45% for MCF-7 cells at 72 h, even at the lowest TLM concentration, indicating better anticancer efficiency than TLM solution.
CONCLUSION: TLM nanoparticles could be potential anticancer agents for breast cancer and deserve further studies. ©Copyright 2020 Turk J Pharm Sci, Published by Galenos Publishing House.

Entities:  

Keywords:  Telmisartan; anticancer effect; drug repositioning; nanoparticles

Year:  2020        PMID: 33177929      PMCID: PMC7650737          DOI: 10.4274/tjps.galenos.2019.76402

Source DB:  PubMed          Journal:  Turk J Pharm Sci        ISSN: 1304-530X


  28 in total

1.  Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer.

Authors:  Takeo Kosaka; Akira Miyajima; Eiji Takayama; Eiji Kikuchi; Jun Nakashima; Takashi Ohigashi; Tomohiko Asano; Michiie Sakamoto; Hajime Okita; Masaru Murai; Masamichi Hayakawa
Journal:  Prostate       Date:  2007-01-01       Impact factor: 4.104

2.  Therapeutic targeting of angiotensin II receptor type 1 to regulate androgen receptor in prostate cancer.

Authors:  Satoru Takahashi; Hiroji Uemura; Azman Seeni; Mingxi Tang; Masami Komiya; Ne Long; Hitoshi Ishiguro; Yoshinobu Kubota; Tomoyuki Shirai
Journal:  Prostate       Date:  2012-03-16       Impact factor: 4.104

3.  Telmisartan inhibits human urological cancer cell growth through early apoptosis.

Authors:  Masahide Matsuyama; Kiyoaki Funao; Katsuyuki Kuratsukuri; Tomoaki Tanaka; Yutaka Kawahito; Hajime Sano; Jamel Chargui; Jean-Louis Touraine; Norio Yoshimura; Rikio Yoshimura
Journal:  Exp Ther Med       Date:  2010-03-01       Impact factor: 2.447

4.  Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers.

Authors:  J Stangier; J Schmid; D Türck; H Switek; A Verhagen; P A Peeters; S P van Marle; W J Tamminga; F A Sollie; J H Jonkman
Journal:  J Clin Pharmacol       Date:  2000-12       Impact factor: 3.126

5.  Preparation and characterization of poly(DL-lactide-co-glycolide) nanoparticles for siRNA delivery.

Authors:  Dongmei Cun; Camilla Foged; Mingshi Yang; Sven Frøkjaer; Hanne Mørck Nielsen
Journal:  Int J Pharm       Date:  2009-10-15       Impact factor: 5.875

6.  Sigma-2 receptor ligand anchored telmisartan loaded nanostructured lipid particles augmented drug delivery, cytotoxicity, apoptosis and cellular uptake in prostate cancer cells.

Authors:  Richa Puri; Richa Kaur Bhatia; Ravi Shankar Pandey; Upendra Kumar Jain; Om Prakash Katare; Jitender Madan
Journal:  Drug Dev Ind Pharm       Date:  2016-06-01       Impact factor: 3.225

7.  Fabrication and evaluation of pH-modulated solid dispersion for telmisartan by spray-drying technique.

Authors:  Nirmal Marasini; Tuan Hiep Tran; Bijay Kumar Poudel; Hyuk Jun Cho; Young Keun Choi; Sang-Cheol Chi; Han-Gon Choi; Chul Soon Yong; Jong Oh Kim
Journal:  Int J Pharm       Date:  2012-11-19       Impact factor: 5.875

8.  The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases.

Authors:  Sandeep Tyagi; Paras Gupta; Arminder Singh Saini; Chaitnya Kaushal; Saurabh Sharma
Journal:  J Adv Pharm Technol Res       Date:  2011-10

9.  Preparation and characterization of liquisolid compacts for improved dissolution of telmisartan.

Authors:  Naveen Chella; Nataraj Narra; Tadikonda Rama Rao
Journal:  J Drug Deliv       Date:  2014-10-12

10.  Telmisartan exerts anti-tumor effects by activating peroxisome proliferator-activated receptor-γ in human lung adenocarcinoma A549 cells.

Authors:  Juan Li; Lin Chen; Ping Yu; Bin Liu; Jiang Zhu; Ye Yang
Journal:  Molecules       Date:  2014-03-05       Impact factor: 4.411

View more
  1 in total

Review 1.  Repositioning of drugs for Parkinson's disease and pharmaceutical nanotechnology tools for their optimization.

Authors:  Héctor Hernández-Parra; Hernán Cortés; José Arturo Avalos-Fuentes; María Del Prado-Audelo; Benjamín Florán; Gerardo Leyva-Gómez; Javad Sharifi-Rad; William C Cho
Journal:  J Nanobiotechnology       Date:  2022-09-15       Impact factor: 9.429

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.